Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04356950
Other study ID # PHRC-I/2020/JCG-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 28, 2020
Est. completion date June 2, 2022

Study information

Verified date September 2022
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Increased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death. Understanding this acquired coagulopathy is a prerequisite before specific interventional studies. The study investigators aim to apply a normalized and automated thrombin generation test (TGT), developed for testing the thrombotic risk (triggered by 5 pM Tissue Factor, with a purified thrombomodulin (TM) challenge) and to study its association with survival.


Description:

Accumulating data describe, in COVID-19 severely infected patients necessitating hospitalized medical support, the development of an acquired coagulopathy, from a sepsis-induced coagulopathy to an overt-DIC, which is a strong risk factor for death. Understanding this coagulopathy is a prerequisite before specific interventional studies. Conventional coagulation tests, like prothrombin time PT and aPTT, only reflect 5% of the total thrombin generation and are insensitive to the patients' natural anticoagulants. The investigators thus wish to analyze the coagulopathy of SARS-CoV-2 using a global analytical test reflecting the full complexity of thrombin generation then inhibition, the thrombin generation test (TGT), in its version designed to analyze the thrombotic risk (initiation by an intermediate concentration of human Tissue: 5 pM), in its fully automated and standardized technical version. This test analyzes not only the generation of thrombin and its various informative phases (initiation phase, propagation phase culminating at the peak of formation, inhibition phase with natural anticoagulants) but also the capacity for an exogenous addition of purified thrombomodulin (TM), which quantifies the anticoagulant activity of the patient's protein C activated by thrombin, to inhibit this generation of thrombin. The aim is to assay this TGT version in a centralized way, on the patients' plasma obtained at hospital admission, just after checking the positive COVID-19 testing , together with the traditional blood tests including platelet counts, PT, D-dimers (DDi) and soluble fibrin monomers (FMs). The various quantitative biological parameters describing the results of the TGT assay, together with relevant covariates, will be tested using multivariate analysis for their capacity to be risk factors for clinically-relevant qualitative outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 175
Est. completion date June 2, 2022
Est. primary completion date February 14, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with SARS-CoV-2 infection entering hospitalization with or without resuscitation - The patient (or their carer) must have given their free and informed consent and signed the consent form - The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: - Pregnant or breastfeeding patient - It is impossible to give the subject informed information - The patient is under safeguard of justice or state guardianship - Thrombotic events during treatment: flare-up of venous thromboembolism, flare-up of atherothrombosis. - Long-term anticoagulant treatment (anti-vitamin K, direct oral anticoagulant). - Chronic anti-aggregation treatment. - Pre-existing constitutive or acquired known coagulation pathology: hemorrhagic diseases (thrombocytopenia, thrombocytopathy, hemophilia, von Willebrand's disease, hemorrhagiparous factor deficiency), and for thrombophilia (deficits in antithrombin, protein C or S , Factor V Leiden or Prothrombin 20201A mutation).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Thrombin generation test assay
lag time, initial velocity, time-to-peak, thrombin peak, total thrombin generation time, extrinsic thrombin potential (ETP). Crude quantitative values and relative values (%, by reference to the one obtained with an invariant reference plasma). Both without the addition of purified thrombomodulin (TM-) and with the addition of purified thrombomodulin (TM+). The ability of TM to inhibit thrombin generation will be calculated as follows: [ETP (%)(TM+) / ETP (%)(TM-)].
Fibrin generation markers assays
D-dimers (coagulation plus fibrinolysis), soluble fibrin monomers (coagulation only)

Locations

Country Name City State
France CHU de Bordeaux Bordeaux
France CHU de Limoges Limoges
France CHU de Montpellier Montpellier
France CHU de Nimes Nîmes

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary 28-day survival rate Death yes/no during hopstilization, 28 days after admittence 1 month
Primary Absolute thrombin generation test latent period Seconds; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Relative thrombin generation test latent period compared to reference plasma %; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Absolute thrombin generation test initial velocity nmol/s; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Relative thrombin generation test initial velocity compared to reference plasma %; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Relative thrombin generation test peak thrombin compared to reference plasma %; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Absolute thrombin generation test peak thrombin nmol/L; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Absolute thrombin generation test peak thrombin time Seconds; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Relative thrombin generation test peak thrombin time compared to reference plasma %; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Absolute thrombin generation test total thrombin generation time seconds; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Relative thrombin generation test total thrombin generation time compared to reference plasma %; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Absolute thrombin generation test endogenous thrombin potential Seconds; without (TM-) and with (TM+) purified thrombomodulin Day 0
Primary Relative thrombin generation test endogenous thrombin potential compared to reference plasma %; without (TM-) and with (TM+) purified thrombomodulin Day 0
Secondary 3-month survival rate Death yes/no 3 months
Secondary Transfer to intensive care unit during hospitalization Yes/no 3 months
Secondary Thrombotic complication during hospitalization Yes/no (deep vein thrombosis, pulmonary embolism, atherothrombosis flare, arterial thrombosis) 3 months
Secondary Plasma concentrations of D-dimers µg / L, assayed by automated enzyme linked fluorescent assay (Vidas® D-dimers Exclusion ™ II) Day 0
Secondary Plasma concentrations of soluble fibrin monomers mg / L, measured by automated immunoagglutination (STA®-Liatest® FM) Day 0
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure